AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On November 25, 2025, , . , , . , , ranking 47th in market activity. Over the past year, , . , . Analysts on MarketBeat maintain a “Moderate Buy” consensus, , indicating modest upside potential.
The U.S. , , dominated headlines. , . , . The move underscores broader regulatory risks for pharma firms with significant U.S. exposure, particularly those reliant on mature products. , .
. , alongside mentorship from
executives. Focused on , , and , the initiative aligns with AbbVie’s therapeutic priorities and reflects a shift toward leveraging external R&D ecosystems. , . , .
, , . , . , , . , . . , .
, . , . . . However, , .
. . , it strengthens the company’s long-term narrative. Additionally, . .
, , , . , , , . , , signal a broader shift toward price controls in the U.S., . , , . .
Hunt down the stocks with explosive trading volume.

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025

Dec.04 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet